The following criteria is provided for health care professionals.

Key Inclusion Criteria:

• Confirmed diagnosis of metastatic treatment-resistant ovarian cancer (including cancers of the fallopian tube), pancreatic adenocarcinoma, hormone receptor (HR)-negative and HER2-negative (triple negative) breast cancer (TNBC) or non-small cell lung cancer (NSCLC), or relapsed/refractory multiple myeloma
• Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
• Prior therapies as defined by tumor type: Multiple myeloma: relapsed or refractory disease previously treated with at least three different lines of therapy; NSCLC: received standard therapy including both checkpoint inhibition and platinum-based chemotherapy; Pancreatic adenocarcinoma: disease progression following at least one standard of care systemic chemotherapy; TNBC: disease progression following at least one prior systemic anti-cancer therapy regimen; patients with PD-L1-positive disease must have received a PD-L1 or PD-1 pathway inhibitor; Ovarian: platinum-resistant and must have received at least two lines of therapy for metastatic disease
• Evaluable disease as defined by tumor type
• TnMUC1+ disease, determined by centrally tested TnMUC1 expression in a prior or archival tumor biopsy
• Completed prior anti-cancer therapy at least 2 weeks prior to Screening and toxicities from any previous therapy must have recovered to grade 1 or 0
• Life expectancy greater than 3 months
• Serum creatinine ≤ 1.2 mg/dL or calculated creatinine clearance ≥ 60 ml/min (using the Cockcroft-Gault formula)
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 x upper institutional limit of normal with the following exception: Patients with known hepatic metastases, AST or ALT ≤ 3 x upper institutional limit of normal
• Serum total bilirubin < 1.5 mg/dL with the following exception: patients with known Gilbert's disease, serum total bilirubin < 3 mg/dL
• Serum albumin ≥ 3.0 g/dL (solid tumor patients in Arm 1 and Phase 1a only, not applicable to patients with multiple myeloma)
• Left ventricular ejection fraction (LVEF) ≥ 50%. LVEF assessment must have been performed within 8 weeks of screening
• Hemoglobin ≥ 9 g/dL
• Absolute neutrophil count ≥ 1500/μL
• Platelet count ≥ 100,000/μL (≥ 30,000/μL if bone marrow plasma cells are ≥ 50% of cellularity for myeloma patients)
• Absolute lymphocyte count of > 500/μL

Key Exclusion Criteria:

• Active invasive cancer other than the proposed cancers included in the study
• Current treatment with systemic high-dose corticosteroids (defined as a dose greater than the equivalent of prednisone 20 mg/day)
• Active autoimmune disease (including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease or multiple sclerosis) or have a history of severe autoimmune disease requiring prolonged immunosuppressive therapy (any immunosuppressive therapy should have been stopped within 6 weeks prior to screening visit)
• Current, active human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) infections
• Prior allogeneic stem cell transplant
• Active and untreated central nervous system (CNS) malignancy
• History of severe infusion reaction to monoclonal antibodies or biological therapies, or to study product excipients that would preclude the patient safely receiving CART-TnMUC1 cells
• Active or recent (within the past 6 months prior to apheresis) cardiac disease, defined as (1) New York Heart Association (NYHA) Class III or IV heart failure, (2) unstable angina or (3) a history of recent (within 6 months) myocardial infarction or sustained (> 30 second) ventricular tachyarrhythmias
• Have inadequate venous access for or contraindications for the apheresis procedure
• Pregnant or breastfeeding women

Key Inclusion Criteria:

• Confirmed diagnosis of metastatic treatment-resistant ovarian cancer (including cancers of the fallopian tube), pancreatic adenocarcinoma, hormone receptor (HR)-negative and HER2-negative (triple negative) breast cancer (TNBC) or non-small cell lung cancer (NSCLC), or relapsed/refractory multiple myeloma
• Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
• Prior therapies as defined by tumor type: Multiple myeloma: relapsed or refractory disease previously treated with at least three different lines of therapy; NSCLC: received standard therapy including both checkpoint inhibition and platinum-based chemotherapy; Pancreatic adenocarcinoma: disease progression following at least one standard of care systemic chemotherapy; TNBC: disease progression following at least one prior systemic anti-cancer therapy regimen; patients with PD-L1-positive disease must have received a PD-L1 or PD-1 pathway inhibitor; Ovarian: platinum-resistant and must have received at least two lines of therapy for metastatic disease
• Evaluable disease as defined by tumor type
• TnMUC1+ disease, determined by centrally tested TnMUC1 expression in a prior or archival tumor biopsy
• Completed prior anti-cancer therapy at least 2 weeks prior to Screening and toxicities from any previous therapy must have recovered to grade 1 or 0
• Life expectancy greater than 3 months
• Serum creatinine ≤ 1.2 mg/dL or calculated creatinine clearance ≥ 60 ml/min (using the Cockcroft-Gault formula)
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 x upper institutional limit of normal with the following exception: Patients with known hepatic metastases, AST or ALT ≤ 3 x upper institutional limit of normal
• Serum total bilirubin < 1.5 mg/dL with the following exception: patients with known Gilbert's disease, serum total bilirubin < 3 mg/dL
• Serum albumin ≥ 3.0 g/dL (solid tumor patients in Arm 1 and Phase 1a only, not applicable to patients with multiple myeloma)
• Left ventricular ejection fraction (LVEF) ≥ 50%. LVEF assessment must have been performed within 8 weeks of screening
• Hemoglobin ≥ 9 g/dL
• Absolute neutrophil count ≥ 1500/μL
• Platelet count ≥ 100,000/μL (≥ 30,000/μL if bone marrow plasma cells are ≥ 50% of cellularity for myeloma patients)
• Absolute lymphocyte count of > 500/μL

Key Exclusion Criteria:

• Active invasive cancer other than the proposed cancers included in the study
• Current treatment with systemic high-dose corticosteroids (defined as a dose greater than the equivalent of prednisone 20 mg/day)
• Active autoimmune disease (including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease or multiple sclerosis) or have a history of severe autoimmune disease requiring prolonged immunosuppressive therapy (any immunosuppressive therapy should have been stopped within 6 weeks prior to screening visit)
• Current, active human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) infections
• Prior allogeneic stem cell transplant
• Active and untreated central nervous system (CNS) malignancy
• History of severe infusion reaction to monoclonal antibodies or biological therapies, or to study product excipients that would preclude the patient safely receiving CART-TnMUC1 cells
• Active or recent (within the past 6 months prior to apheresis) cardiac disease, defined as (1) New York Heart Association (NYHA) Class III or IV heart failure, (2) unstable angina or (3) a history of recent (within 6 months) myocardial infarction or sustained (> 30 second) ventricular tachyarrhythmias
• Have inadequate venous access for or contraindications for the apheresis procedure
• Pregnant or breastfeeding women